ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Edronax®:Pfizer AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
N06AX18 - ReboxetineATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N06 - Psychoanaleptics

This group comprises antidepressants, psychostimulants, nootropics, anti-dementia drugs and combinations with psycholeptics.
Antiobesity preparations are classified in A08 - Antiobesity preparations, excl. diet products.

N06A - Antidepressants

This group comprises preparations used in the treatment of endogenous and exogenous depressions.
The group is subdivided mainly according to mode of action. The various antidepressants have different modes of action, and the classification will not reflect the exact mode of action of the various antidepressants.
Lithium, see N05AN - Lithium
Combination with psycholeptics, see N06C.

The DDDs are based on treatment of moderately severe depressions.

N06AX - Other Antidepressants

This group includes antidepressants, which cannot be classified in the preceding groups.
Esketamine for nasal administration is classified here, while injections are classified in N01AX.

N06AX18 - Reboxetine
StärkeAdm.RouteNote
 O 
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home